TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ALKS

Alkermes Plc

Healthcare · Drug Manufacturers - Specialty & Generic

43.40$ -7.1% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Cash Flow

Alkermes Plc (ALKS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at 521 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow ALKS
Line item 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-17 -1.1 -14 -33 -18 -43 -49 -98 -74 117 84 42 35 -12 -5.9 -2.5 127 92 11 -40 -64 19 99 72 83 102 21 401 439 521
2.6 2.7 22 6.4 7.7 11 9.3 11 11 11 12 12 10 25 8.7 94 74 71 98 86 94 99 104 80 82 79 78 75 29 27
15 14 29 29 41 60 97 94 84 105 101 90 88 94 101 97 99
19 52 17 -38 19 78 83 145 123 99 97 89
-1.0 6.5 4.9 -1.4 -7.1 2.4 28 -11 -24 96 31 1.6 -123 -15 8.4 -1.1 -15 147 11 82 -27 -4.9 -7.4 65 13 -26 13 -37 -98 119
2.2 8.0 24 5.8 10 33 46 15 18 29 36 22 5.5 16 9.4 17 22 19 34 53 44 51 69 91 42 29 38 48 33 40
-57 -113 4.5 -195 21 42 32 -81 -39 -138 -30 62 45 28 5.6 -417 -68 -177 -263 -43 127 -18 -22 -142 -11 -66 -65 53 -111 295
7.5 9.2 7.3 0.0 0.0 0.0 0.0 0.0 0.0 9.6 0.7 8.7 1.4
0.0 0.0 -12 -93 -18 -2.7 -2.7 -3.7 17 -12 49 -13 -26 -13 -16 -20 -9.3 -7.7 -17 -18 -28 -200 -31
443 -83 -8.8 -6.8 -6.8 -69 -3.0 -2.9 -2.8 -2.8 20 -3.0 -3.0 -292 0.0
76 115 15 225 -3.3 11 73 117 151 7.4 -6.7 -84 -94 -23 -41 465 -45 44 309 41 -58 4.1 -1.6 6.8 -2.2 29 -1.6 -290 -494 12
2.4 0.7 5.4 -3.0 -0.2 10 56 -63 38 -14 47 21 -14 -7.6 -41 45 13 71 57 -43 5.3 4.9 75 -63 69 65 -45 165 -166 829
-19 -9.1 -38 -39 -28 -76 -95 -113 -92 88 47 21 29 -28 -15 -19 104 73 -23 -93 -107 -32 30 -19 41 73 -17 353 406 480

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?